NCT00804310终止1 期
Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- Safety and Toxicity
研究概览
简要总结
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with ixabepilone may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib given together with ixabepilone in treating patients with advanced solid tumors.
详细描述
OBJECTIVES:
Primary
- To evaluate the safety and feasibility of lapatinib ditosylate in combination with ixabepilone in patients with advanced solid tumors.
Secondary
- To determine the maximum-tolerated dose of this regimen in these patients.
- To assess, preliminarily, the efficacy of this regimen in these patients.
- To perform laboratory correlative studies on tissue and blood specimens from these patients to investigate potential predictors of response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have cytologically or histologically proven advanced solid tumors for which there is no known standard therapy available or are not eligible for standard therapy because of their performance status, or have progressed after standard therapy.
- •Patients must have measurable or evaluable disease
- •Patients must be 18 years of age or older
- •Patients must have a Zubrod performance status of 0-2
- •Patients must have an estimated survival of at least 3 months
- •Any prior chemotherapy must have been completed at least 3 weeks prior to start of this protocol and all side effects (except alopecia) resolved to grade 1 or less. Any prior radiation must have been completed at least 2 weeks prior to start of therapy. Patients must have completed prior trastuzumab (Herceptin) at least 4 weeks prior to start of protocol therapy
- •Patients must have adequate renal function
- •Patients must have adequate liver function
- •Patients must have a pretreatment granulocyte count of >1500/mm3 and platelet count of >100 000/mm
- •Patients must have a cardiac ejection fraction within the institutional range of normal as measured by 2-D echocardiogram or MUGA scan.
- •All patients must give informed consent
- •Patients must be able to take and retain oral medication
- •Patients of reproductive potential must agree to use an effective contraceptive method while on treatment as the effects of these drugs on the unborn fetus are unknown.
排除标准
- •Patients may not have previously received lapatinib, ixabepilone or any other EGFR-TKI targeted agent. Prior trastuzumab (Herceptin) is allowed.
- •Patients may not pregnant or breastfeeding as the effects of these drugs on the unborn fetus are unknown.
- •Patients with symptomatic brain metastasis or still requiring steroids and anticonvulsants may not participate. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) may be included if they are neurologically stable and have been off steroids for at least 2 weeks.
- •Patients with pre-existing neuropathy > grade 2 may not participate.
- •Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, will be excluded.
- •History of other diseases, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications.
- •Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or prior surgical procedures affecting absorption.
- •HIV-positive patients receiving combination antiretroviral therapy are excluded from the study because of possible pharmacokinetic interactions with lapatinib. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
- •Patients requiring oral anticoagulants are eligible provided there is appropriate close INR monitoring in place.
- •Prior radiation must not have included more than 30% of bone marrow containing areas
- •Any prior, severe history of hypersensitivity reaction to a drug formulated in CremaphorEL
- •Adherence to the requirements for concomitant medications classified as CYP3A4 inducers or inhibitors, or gastric pH modifiers
研究组 & 干预措施
Lapatinib and Ixabepilone
Experimental
干预措施: ixabepilone (Drug)
Lapatinib and Ixabepilone
Experimental
干预措施: lapatinib ditosylate (Drug)
结局指标
主要结局
Safety and Toxicity
时间窗: Toxicity will be assessed at the beginning of every cycle and on day 8 and 15 of every cycle for at least eight weeks (2 cycles). Maximum of 6 cycles.
Assessed by NCI CTCAE v 3.0
次要结局
- Preliminary efficacy(One year)
- Maximum tolerated dose (MTD)(One cycle (4 weeks))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerBreast CancerNCT00513058UNICANCER33
已完成
2 期
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or CarboplatinPeritoneal Cavity CancerOvarian CancerNCT00436644Mayo Clinic18
已完成
1 期
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2Metastatic CancerBreast CancerNCT00544804University of California, San Francisco41
已完成
2 期
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerNCT00113373National Cancer Institute (NCI)28
已完成
1 期
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00389922University of California, Davis22